Patents by Inventor CÉDRIC MALICET

CÉDRIC MALICET has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR CANCER IMAGING AND RADIOTHERAPY
    Publication number: 20240100204
    Abstract: The present invention relates to a conjugated compound comprising a marker M pharmaceutically acceptable, and a peptide or pseudo-peptide P having at most 30 amino acid residues and able to bind the Low-Density Lipoprotein Receptor (LDLR) and to its use in a method of labelling and/or detecting and/or treating cancerous cells in a subject by administration of the conjugated compound to the subject an analysis of the presence and/or the amount of marker.
    Type: Application
    Filed: July 28, 2023
    Publication date: March 28, 2024
    Inventors: CÉDRIC MALICET, PASCALINE LECORCHE, JONATHAN NOWAK, MARION DAVID, JAMAL TEMSAMANI, MICHEL KHRESTCHATISKY
  • Compositions and methods for cancer imaging and radiotherapy
    Patent number: 11712486
    Abstract: The present invention relates to a conjugated compound comprising a marker M pharmaceutically acceptable, and a peptide or pseudo-peptide P having at most 30 amino acid residues and able to bind the Low-Density Lipoprotein Receptor (LDLR) and to its use in a method of labelling and/or detecting and/or treating cancerous cells in a subject by administration of the conjugated compound to the subject an analysis of the presence and/or the amount of marker.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: August 1, 2023
    Assignees: VECT-HORUS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'AIX-MARSEILLE
    Inventors: Cédric Malicet, Pascaline Lecorche, Jonathan Nowak, Marion David, Jamal Temsamani, Michel Khrestchatisky
  • COMPOSITIONS AND METHODS FOR CANCER IMAGING AND RADIOTHERAPY
    Publication number: 20190351079
    Abstract: The present invention relates to a conjugated compound comprising a marker M pharmaceutically acceptable, and a peptide or pseudo-peptide P having at most 30 amino acid residues and able to bind the Low-Density Lipoprotein Receptor (LDLR) and to its use in a method of labelling and/or detecting and/or treating cancerous cells in a subject by administration of the conjugated compound to the subject an analysis of the presence and/or the amount of marker.
    Type: Application
    Filed: January 30, 2018
    Publication date: November 21, 2019
    Inventors: CÉDRIC MALICET, PASCALINE LECORCHE, JONATHAN NOWAK, MARION DAVID, JAMAL TEMSAMANI, MICHEL KHRESTCHATISKY